RxDoctor Payments Data

John Palmer, DO

Endocrinology, Diabetes & Metabolism · Rapid City, SDNPI 1063510691

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $390,815 of the $418,585 with a category attached, or 93.4%. 22 manufacturers reported payments, led by Novo Nordisk at 35.1% of the total. Reporting peaked in 2019 at $121,942 and has fallen 96.9% since, to $3,757 in 2025. Among endocrinology, diabetes & metabolism clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$418,585in general payments, 2019–2025

Across 811 payments — averaging $516.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$147K
  • Lilly USA, LLC$91K
  • Sanofi-aventis U.S. LLC$64K
  • AstraZeneca$36K
  • Dexcom, Inc.$27K
  • Boehringer Ingelheim$24K
  • plus $29K from 16 others

What the payments were for

  • Consulting fees$2,9251%
  • Speaking & faculty fees$390,81593%
  • Travel & lodging$13,4233%
  • Food & beverage$10,9083%
  • Education$5140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$418,585 in reported general payments places this provider in the 95th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.

See all endocrinology, diabetes & metabolism providers in South Dakota

Medicare billing

Part B allowed, 2024
$185,529
Medicare patients
850
Services billed
2,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa26$2,248,698
OzempicSemaglutide605$810,074
JardianceEmpagliflozin392$450,654
MounjaroTirzepatide264$377,868
Soliqua 100-33Insulin Glargine/Lixisenatide165$237,937
TrulicityDulaglutide106$142,310
Tresiba Flextouch U-100Insulin Degludec236$141,213
Tresiba Flextouch U-200Insulin Degludec117$116,573
FarxigaDapagliflozin Propanediol109$113,679
Fiasp FlextouchInsulin Aspart (Niacinamide)111$108,664
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog137$100,061
JanuviaSitagliptin Phosphate78$74,979
Novolog FlexpenInsulin Aspart249$74,503
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog52$74,178
RybelsusSemaglutide24$51,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaStrensiq, Farxiga$36,334$2,362,378135 claims
Novo NordiskOzempic, Rybelsus, Fiasp, Xultophy 100-3.6$146,986$941,518690 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$91,469$531,787416 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta$24,143$477,588439 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$64,169$237,937165 claims
Johnson & JohnsonInvokana$20,511$22,13222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 endocrinology, diabetes & metabolism providers in South Dakota.

Other endocrinology, diabetes & metabolism in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →